<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
TARRYTOWN, N.Y. and PARIS, July 29, 2021 /PRNewswire/ — Fifth disease in which Dupixent has demonstrated positive pivotal results Phase 3 trial met primary and all key secondary endpoints at 24 weeks, showing Dupixent nearly doubled reduction in itch and urticaria activity scores CSU results further demonstrate the potential of targeting IL-4 and IL-13 via IL-4Ra blockade to improve diseases with components of type 2 inflammation Approximately 300,000 people in the U.S. have moderate-to-severe CSU that does not respond adequately to antihistamines alone Data continue to support well-established safety profile of Dupixent Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced a pivotal Phase 3 trial evaluating Dupixent® (dupilumab) in patients with moderate-to-severe chronic spontaneous urticaria (CSU) met its primary and all key secondary endpoints at 24 weeks.
...read full article on PRNewsWire
